Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 45Recurrence 14Lymphoma 6Neoplasms 5Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 4Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Hodgkin Disease 2Glioblastoma 2Amyloidosis 2Wilms Tumor 1Vomiting 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Ototoxicity 1Osteosarcoma 1Obesity 1Neoplasms, Germ Cell and Embryonal 1Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

Dexamethasone 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Ototoxicity × Dexamethasone × Clear all
NCT02382068 2017-11-09

Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin

Ohio State University Comprehensive Cancer Center

Phase NA Withdrawn

Ototoxicity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡